Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit

Alberto Dalla Volta; Anna Maria Formenti; Alfredo Berruti

doi:10.1016/j.eururo.2019.01.026

Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit

Eur Urol. 2019 Jun;75(6):894-895. doi: 10.1016/j.eururo.2019.01.026. Epub 2019 Jan 31.

Authors

Alberto Dalla Volta¹, Anna Maria Formenti¹, Alfredo Berruti²

Affiliations

¹ Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.
² Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy. Electronic address: alfredo.berruti@gmail.com.

PMID: 30711330
DOI: 10.1016/j.eururo.2019.01.026

Abstract

Results from the ERA 223 trial of abiraterone combined with radium-223 among men with chemotherapy-naïve castration-resistant prostate cancer and bone metastases show no improvement in survival free from symptomatic skeletal events. We hypothesize that this finding might be attributable to bone loss induced by the concomitantly administered prednisone.

Publication types

Editorial
Comment

MeSH terms

Abiraterone Acetate
Androstenes
Antineoplastic Combined Chemotherapy Protocols
Fractures, Bone*
Humans
Male
Prednisone
Prostatic Neoplasms, Castration-Resistant*
Radium*
Treatment Outcome

Substances

Androstenes
Radium-223
Abiraterone Acetate
abiraterone
Prednisone
Radium